IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation. Biomol Biomed [Internet]. 2022 Jul. 29 [cited 2024 May 2];22(4):580-92. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7279